Aktuellt
SENASTE
Redeye gives its initial take on BONESUPPORT’s Q1 report. We note a continuous solid foundation for increasing sales growth and accelerating profitability. Still, we believe the market will focus on the EBIT (disregarding the reasons for the miss) and push the share down today (3-5%). We are unlikely to make significant estimates and valuation changes following the report
LÄS MER
